Plant · Scientific monograph
Pelargonium sidoides
African Geranium / Umckaloabo
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Upper Respiratory Research, Respiratory Research
Research overview
Historical use
Pelargonium root preparations have a documented tradition of use for respiratory complaints; the EMA common-cold indication is based on long-standing traditional use, rather than a finding of well-established clinical efficacy. The EMA monograph covers P. sidoides and/or P. reniforme [1][6].
Modern research context
Proprietary Pelargonium root extracts have been investigated for acute cough and respiratory symptoms, but certainty and formulation differences remain substantial [1][2][3]. The Cochrane review judged evidence low for acute bronchitis and very low for common cold or sinusitis, with suspected publication bias and differences between liquids and tablets [1]. A later meta-analysis of 11 EPs 7630 trials (2195 participants) reported cough improvement; the authors include manufacturer employees or paid consultants, and the analysis does not remove the limitations or establish interchangeability with other products [3]. A UK feasibility trial recruited 134 adults and demonstrated recruitment feasibility rather than definitive efficacy [2]. Archive classification is Level U for a firm clinical efficacy conclusion and Level T for EMA traditional common-cold use [1][6].
Adverse effects
EMA 2024 lists gastrointestinal complaints, nasal or gum bleeding, hypersensitivity including anaphylaxis, rash, pruritus, urticaria, angioedema, hepatitis and hepatotoxicity, with frequency unknown [6]. The Cochrane trials reported more adverse events with extract than placebo, without serious events in those trials [1]. Liver causality remains disputed: a case reassessment found none of 15 reports probable or highly probable, but this does not negate current regulatory warnings [4][6].
Contraindications
Hypersensitivity is an EMA contraindication. Signs of liver injury require stopping the product and medical assessment [6]. The 2024 monograph does not recommend oral use below age three. For its dry-extract preparations b) and c), children under six should receive only liquid dosage forms; a dry extract and a solid finished dosage form are different concepts. Symptoms persisting longer than one week or worsening require medical advice [6]. No evidence-based perioperative washout interval was established in this extraction.
Clinical and phytochemical data
Used part
Root; clinical findings mainly concern proprietary EPs 7630 liquid/dry extracts. EMA describes defined ethanol-extracted preparations and also covers P. reniforme, so genus-level and mixed-species preparations cannot be assumed equivalent to P. sidoides trial material [2][3][6].
Primary active compounds
Root extract is a mixture; no single clinically proven active constituent accounts for the symptom findings [1][3]
Mechanism of action
Experimental work summarized by the EPs 7630 review investigates host-defense signaling, including interferon and tumor necrosis factor, alongside antiviral and mucociliary effects. These are primarily preclinical hypotheses; they do not establish antiviral treatment efficacy, prevention of complications or a clinically validated molecular target [3].
Pharmacokinetics
Absorption
Human constituent-specific absorption and absolute bioavailability were not established in the selected clinical sources; EMA traditional-use monograph does not provide pharmacokinetic parameters [1][6].
Distribution
Human tissue distribution and protein binding of whole root extracts remain insufficiently characterized in the selected sources [6].
Metabolism
Complete human metabolic pathways and clinically relevant CYP effects were not established in the selected sources [6].
Excretion
Validated whole-extract half-life, renal clearance and impairment adjustments are unavailable in the selected sources [6].
Safety and interactions
Drug interactions
EMA reports no interactions, which is not proof that all combinations are safe [6]. Nasal and gingival bleeding are reported adverse reactions; a clinically quantified interaction with anticoagulants or antiplatelets was not established in this extraction. Medication review remains prudent [6].
Toxicity
Hepatitis and hepatotoxicity reports remain in current EMA warnings even though causality was not substantiated in one reassessment [4][6]. A manufacturer-sponsored, non-interventional 2026 study enrolled 300 adults (298 completing) and reported no clinical signs of liver injury after a seven-day PELARGO capsule course. Short follow-up and symptom-based surveillance cannot rule out rare, delayed or asymptomatic injury [5]. Product-specific findings cannot establish long-term safety of all root extracts.
Special precautions
Pregnancy
Safety in pregnancy is not established and EMA does not recommend medicinal use [6].
Lactation
Milk transfer and infant safety are unknown; EMA does not recommend medicinal use during breastfeeding [6].
Hepatic impairment
No validated impairment adjustment identified. Reported hepatitis/hepatotoxicity warrants particular caution in existing liver disease and immediate medical assessment of possible liver-injury symptoms [6].
Renal impairment
No validated renal-impairment adjustment or adequate disease-specific safety data identified in selected sources [6].
Sources and references
- [1] - Timmer A, Günther J, Motschall E, Rücker G, Antes G, Kern WV. Pelargonium sidoides extract for treating acute respiratory tract infections. The Cochrane database of systematic reviews, 2013. PMID: 24146345. DOI: 10.1002/14651858.cd006323.pub3
- [2] - Willcox M, Simpson C, Wilding S, Stuart B, Soilemezi D, Whitehead A, Morgan A, Wrixon E, Zhu S, Yao G, Webley F, Yan R, Bostock J, Bell M, Griffiths G, Leydon G, Little P, Butler C, Hay AD, Moore M. Pelargonium sidoides root extract for the treatment of acute cough due to lower respiratory tract infection in adults: a feasibility double-blind, placebo-controlled randomised trial. BMC complementary medicine and therapies, 2021. PMID: 33514367. DOI: 10.1186/s12906-021-03206-4
- [3] - Kardos P, Lehmacher W, Zimmermann A, Brandes-Schramm J, Funk P, Matthys H, Kamin W. Effects of Pelargonium sidoides extract EPs 7630 on acute cough and quality of life - a meta-analysis of randomized, placebo-controlled trials. Multidisciplinary respiratory medicine, 2022. PMID: 36051888. DOI: 10.4081/mrm.2022.868
- [4] - Teschke R, Frenzel C, Schulze J, Eickhoff A. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained? Regulatory toxicology and pharmacology : RTP, 2012. PMID: 22381150. DOI: 10.1016/j.yrtph.2012.02.009
- [5] - Alvero RGY, Balmadrid AS, Aquino RCC, Balaccua GP. Short-term Liver Safety of Pelargonium sidoides DC. Root (PELARGO) 20 mg Capsule: A Non-interventional Post-authorization Safety Study. Acta medica Philippina, 2026. PMID: 41890334. DOI: 10.47895/amp.vi0.12322
- [6] - EMA/HMPC. European Union herbal monograph on Pelargonium sidoides DC; Pelargonium reniforme Curt., radix. Final revision 2, 29 May 2024. https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-pelargonium-sidoides-dc-pelargonium-reniforme-curt-radix-revision-2_en.pdf